Business Overview: OmniAb, Inc. (Nasdaq: OABI)

---

Executive Summary

OmniAb, Inc. is an antibody-discovery technology licensing company headquartered in Emeryville, California, spun off from Ligand Pharmaceuticals in November 2022. Rather than developing its own drugs, OmniAb licenses a suite of proprietary transgenic animal and AI-enabled antibody discovery platforms to pharmaceutical and biotech partners, who use them to generate antibody candidates for their own drug pipelines.

It is a "picks-and-shovels" play on the broader biologics industry: as of year-end 2025 OmniAb had 107 active partners running 407 active discovery programs, with 27 OmniAb-derived antibodies already in partner clinical development, 2 under regulatory review, and 3 already approved as marketed drugs — a long tail of optionality funded almost entirely by other companies' R&D budgets rather than OmniAb's own.

---

1. Core Business Model & How They Work

OmniAb doesn't sell antibodies or drugs directly — it licenses the discovery engine that generates them, then shares in the economics of whatever its partners eventually commercialize.

[ License OmniAb platform to partner ] ➡️ [ Partner generates antibody candidates using OmniAb animals/software ] ➡️ [ Partner advances candidate through clinic ] ➡️ [ Milestone payments to OmniAb ] ➡️ [ Drug approved & commercialized ] ➡️ [ Royalties to OmniAb on net sales ]

Key Operational Drivers

1. Upfront and access fees: Partners typically pay technology access fees (upfront or annual) simply to use the platforms, providing a base layer of revenue independent of any single program's success.
2. Milestone payments: As partner programs hit development and commercial milestones, OmniAb earns payments — this is the largest near-term revenue driver given how early-stage the overall partner portfolio still is.
3. Royalties: Low- to mid-single-digit royalties on net sales of any approved, OmniAb-derived drug — the long-term, highest-margin revenue stream, but one that only becomes material as more of the 27 clinical-stage programs (and future programs) reach approval.
4. Academic revenue-sharing: Deals with academic institutions generally use a different, revenue-sharing structure rather than the upfront/milestone/royalty model used with commercial partners.
5. Capital-light model: Because OmniAb itself does not run late-stage clinical trials, its own cost structure is dominated by R&D/platform development and business development rather than clinical trial spend — of its 89 employees, 63 are in R&D.

---

2. Product Portfolio (Platforms)

---

3. Competitive Landscape

OmniAb competes across several adjacent but distinct toolsets within antibody discovery and broader biologics R&D services.

 ANTIBODY DISCOVERY TOOLS POSITIONING
┌──────────────────────────────────────────────────────────┐
│ High                                                       │
│  ▲                          [Regeneron – VelocImmune]       │
│  P                          (in-house use, limited          │
│  L                           external licensing)            │
│  A           [OmniAb]                                       │
│  T           (multi-species, licensed broadly)              │
│  F                          [AbCellera]                     │
│  O           [Harbour BioMed]                               │
│  R                                                           │
│  M           [Twist Bioscience]                             │
│              (synthetic/display libraries)                  │
│  Low                                                         │
│  └─────────────────────────────────────────────────────►    │
│   Narrow      BREADTH OF LICENSABLE PLATFORMS      Broad     │
└──────────────────────────────────────────────────────────┘

Competitors by Function

• Transgenic animal platforms: AbCellera, Regeneron (whose VelocImmune platform is largely used in-house rather than broadly licensed, reducing direct licensing competition but also showing what a fully-integrated competitor looks like), Harbour BioMed, and synthetic-library players like Twist Bioscience.
• Single-cell screening: Bruker (via its Berkeley Lights/Beacon platform) and Sartorius compete for the high-throughput screening step of the discovery workflow.
• Ion-channel and broader discovery CROs: Charles River Laboratories, Evotec, and WuXi AppTec offer competing or complementary discovery services, often bundled with broader contract research capabilities OmniAb does not provide.
• Traditional hybridoma/phage display CROs: Legacy discovery approaches remain in use at many smaller biotechs, representing the "do it the old way" alternative OmniAb's platforms are trying to displace.

---

4. Strategic Strengths & Risks

Competitive Strengths (The Moat)

• Diversified partner base: 107 active partners across 407 programs means no single clinical failure or partner decision materially impairs the business — a structural advantage over single-asset biotechs.
• Multi-species platform breadth: Offering fully human antibody discovery across rat, mouse, chicken, and cow hosts (plus bispecific-ready and nanobody formats) is a differentiated, patent-protected technical moat that would take years and significant capital for a new entrant to replicate.
• Call-option-like pipeline optionality: 27 clinical-stage antibodies, 2 under regulatory review, and 3 already approved give OmniAb embedded, long-dated royalty optionality funded by partners' own capital.
• Low capital intensity: Because OmniAb does not run its own late-stage trials, it avoids the massive cash burn of a typical clinical-stage biotech.

Strategic Risks & Vulnerabilities

• Still unprofitable and revenue-declining: 2025 revenue of $18.7 million was down ~29% from $26.4 million in 2024, while the net loss widened slightly to $64.8 million — the business is shrinking on the top line even as losses continue.
• Revenue concentration: The top three partners accounted for 37% of 2025 revenue, meaning a small number of relationship changes could meaningfully move results.
• Long value-realization lag: The bulk of OmniAb's real upside sits in 27 early-to-mid-stage clinical programs that have not yet generated material royalties — most of the embedded value is unrealized and dependent on partners' own clinical and commercial success, which OmniAb cannot control.
• Competitive platform landscape: Well-capitalized rivals like AbCellera and in-house platforms at Regeneron reduce the pool of partners willing to pay for external licensing versus building or buying discovery capability themselves.
• Biotech funding sensitivity: A broader downturn in biotech venture/IPO funding reduces partners' R&D budgets and their appetite for new technology access deals, directly pressuring OmniAb's upfront and service fee revenue.

---

5. Financial Overview

---

6. Summary Conclusion

OmniAb occupies a genuinely differentiated niche as a multi-species, multi-format antibody discovery platform licensor with real patent protection and a broad, diversified partner base that includes 27 clinical-stage programs and 3 already-approved drugs. The core tension in the story is timing: most of the company's real value sits in early- and mid-stage partner programs that have not yet generated meaningful royalties, while current-year revenue is small, lumpy, and actually declined in 2025 even as losses widened. Whether OmniAb becomes a durable royalty business depends on whether enough of its 407 active partner programs eventually clear clinical and regulatory hurdles — a outcome OmniAb can support with its platforms but cannot itself control.